Search

everythinglearnresearchcommunity

for

Search:↓

New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.

New progesterone-based compounds can block male hormones.

A new method was developed to make finasteride for treating hair loss.

The study found that in Eclipta prostrata roots, coumestans come from acetate and shikimate pathways, and phenylpropanoid is made only through the shikimate pathway.

PGD2 increases androgen receptor activity in hair cells, which could be targeted to treat hair loss.

Finasteride may cause changes in dopamine-related genes, possibly leading to post-finasteride syndrome.

The structure of SRD5A reveals how it reduces steroids, aiding drug design for related health conditions.

Prostaglandin D2 increases testosterone levels in skin cells through reactive oxygen species, not enzymes, which could lead to new hair loss treatments.

Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair growth cells and aiding self-repair.

Finasteride modifies 5-alpha-reductases through a two-step process, affecting inhibitor potency and possibly causing side effects.

5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.

Progesterone reduces anxiety and depression in female mice by increasing BDNF in the brain, needing 5α-reduction and estradiol.

Researchers successfully made new compounds for hormone level tests, but one attempt led to an unexpected product, correcting a past error.

The piRNA pathway genes are crucial in early development and may influence sex differentiation through hormone regulation.

The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.

The estrogen receptor pathway controls hair growth cycles and affects skin cell growth.

Finasteride is made through a series of chemical reactions starting from a specific intermediate compound.

Trienones are more effective at inhibiting the enzyme linked to hair loss than dienones.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

New targets for making and using brain-synthesized steroids could lead to better treatments for brain disorders and alcoholism.

Poria cocos polysaccharides and finasteride both help treat chronic nonbacterial prostatitis, but Poria cocos polysaccharides also improve gut health.

Finasteride irreversibly affects human steroid 5α-reductase 2, providing insight into its catalytic mechanism and disease-related mutations.

Signaling pathways are key targets for developing effective drugs.

We need to learn more about 5α-reductases and neuroactive steroids to safely make drugs targeting these enzymes.

Modifying steroidal inhibitors shows promise for developing new cancer treatments.

Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.

New compounds show promise for treating benign prostate hyperplasia with fewer side effects.

Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.

EP 2 receptor is essential for heart repair by helping macrophages work properly.

14,15-EET may help reduce poststroke pain by affecting certain brain proteins.